WO1997035590A1 - 10-aza-9-deoxo-11-deoxy-erythromycin a and derivatives combined with sulfisoxazole - Google Patents

Abstract

Pharmaceutical compositions of an erythromycin derivative combined with sulfisoxazole according to structural formulas (I) and (II) where R is hydrogen; C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl wherein the substituent is amino or cyano; R<1> and R<2> are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.

Description

APPLICATION

Of

CHRIS PLATT

For

UNITED STATES LETTERS PATENT

On

10-Aza-9-Dcoxo-11-Deoxy-Erythromycin A and Derivatives Combined with Suifisoxazole

TITLE: 10-Aza-9-Dcoxo-11-Deoxy-Erythromycin A and Derivatives Combined with

Suifisoxazole

BACKGROUND OF THE INVENTION

Field Of The Invention

The present invention relates to a novel group of chemical compounds providing antibacterial activity, and which are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to compositions including the derivatives of the welUknown antibiotic, erythromycin A.

Description of Related Art The related art includes:

Tarpay et at, Antimicrobial Agents and Chemotherapy, Vol.22, No. 1, pages 145-147 (1982). Hughes et al., J. of Infectious Diseases, Vol. 170, No. 1, pages 906-911, (1994).

Doem et al., Antimicrobial Agents and Chemotherapy, Vol.32, No.2, pages 180-185 (1988). U. S. Patents:

4,328,334 to Korbrehel et al 4,464,527 to Bright et al

4,465,674 to Bright et al 4,492,688 to Bright et al

4,512,982 to Hanske et al 4,517,359 to Kobrehel et al

4,526,889 to Bright et al 4,518,590 to Hanske et at

4,886,792 to Djokie 4,957,905 to Hunt et al

SUMMARY OF THE INVENTION

The erythromycin derivatives act by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfere with microbial protein synthesis. Nucleic acid synthesis is not affected. The suifisoxazole inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the ptcndine with para-aminobenzoic acid through competitive inhibition of the enzyme dihydopteroate synthetase. After absorption the erythromycin derivative is largely bound to plasma proteins and readily diffuses into most body fluids. Rapid distribution of erythromycin derivative into tissues and high concentration within cells results in higher concentrations in tissues than in serum or plasma. Erythromycin derivative seems to concentrate in fibroblasts and phagocytes as demonstrated by in vivo incubation techniques. Such derivatives are modifications of the well-known antibiotic, erythromycin A, having the following structure:

The erythromycin derivatives of the present invention relate to the compounds of the following structure and derivatives thereof, which form a novel class of 14-mcmbcred azalides

characterized in that the heterocyclic nitrogen atom is situated at the 10 position. The inventive step in the present invention is that these compounds are combined with suifisoxazole for enhanced antibacterial activity. The present invention provides for novel pharmaceutical compositions and methods for their use as antibacterial agents.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

An important challenge in regards to antibiotics, is how to avoid the problem of pathological resistance to these medications. By combining two different antibiotics, each having different mechanisms of action, but which work synergistically together this problem can be overcome. The present invention stems from the discovery that certain erythromycin derivatives are easily tolerated by patients without causing gastrointestinal disturbances. Additionally when combined with suifisoxazole, resistance to Entcrococcus Faecalis, methacillin-resistant stapylococci, and erythromycin resistant gram-positive strains is achieved. The inventive combination provides protection from a greater antibacterial spectrum then either erythromycin or suifisoxazole alone. Thus, this new invention not only saves lives by providing a combination that overcomes medication resistance but is more easily tolerated without stomach upset and vomiting; side effects experienced by many people taking erythromycin alone.

Specifically the basis for the present invention is the pharmaceutical composition of an erythromycin derivative combined with acetylsulfisoxazole according to the structural formulas shown in Claim 1 below, where R is hydrogen; C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl wherein said substituent is amino or cyano; and R1 and R2 are independently hydrogen, hydroxyl or amino; and including the pharmaceutical salts and esters thereof. Chemically acetylsulfisoxazole is N-(3,4,-Dimetly-5-isoxazole)-N-sulfanylactamide. Suifisoxazole, where the acetyl group is replaced by H is an alternative substitution in the invention. Alternative possibilities for the erythromycin derivative include, but are not limited to, the structural formulas as shown in either Claim 3 where R is methyl, R' is H and R², in Claim 5 where R is ammino alkyl carbonyi, R¹ is H and R² is OH, and in Claim 6 where R is cyano, R¹ is an ammino group, and R¹ is H.

In an alternate embodiment, the composition of the present invention may be formulated wherein the erythromycin derivative has the general structural formula as shown below in Claim 2, including the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein R¹ is hydrogen, C1-C10 alkyl carbonyi or unsubstituted or substituted C1-C10 alkyl wherein the substituent is amino or cyano; R² and R³ are hydrogen; R¹ and R¹ together are oxo; R⁴ is hydrogen or C1-C10 alkylcarbonyl; R⁵ and R' arc independently hydrogen, hydroxy or amino; R⁵ and R⁶ together are oxo or oximino; R⁷ and R⁸ are independently hydrogen, C1-C10 alkyl or phenylsulfonyl; R⁹ Is hydrogen, or C1-C10 alkylcαrbony, and R ¹⁰ is hydrogen. Examples of operable substitutions for the nine variables include the following:

In formulating the combination of the present invention it has been found that the mixture ratio by weight, of erythromycin to suifisoxazole, may range from 100:1 to as much as 1 :1, and even trace amounts of suifisoxazole may be operative. The preferred ratio is 100:38. The erythromycin and suifisoxazole are prepared following standard laboratory procedures and processes that all competent workers in the field of the present invention will know.

The various alternative formulations of the present invention may take the form of a compressed pill, a powder in an easy to swatlow caplet, or even as a fluid dissolved in a liquid such as water. In all cases, the formulation is to be taken orally.

Claims

1. A pharmaceutical composition of an erythromycin derivative combined with

acetylsulfisoxazole according to the structural formulas:

where R is hydrogen;

C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl wherein said substituent is amino or cyano;

R1 and R2 are independently hydrogen, hydroxyl or amino;

and the pharmaceutical salts and esters thereof.

2. A pharmaceutical composition of a erythromycin derivative combined with

acetylsulfisoxazole according to the structural formula:

and the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein R¹ is hydrogen,

C1-C10 alkylcarbonyl or unsubstituted or substituted

C1-C10 alkyl [where] wherein said substituent is amino or cyano;

R² and R³ are hydrogen;

R² and R³ together are oxo;

R⁴ is hydrogen or C1-C10 alkylcarbonyl;

R³ and R⁶ are independently hydrogen, hydroxy or amino;

R¹ and R⁶ together are oxo or oximino;

R⁷ and R⁸ are independently hydrogen, C1-C10 alkyl or phenylsulfonyl;

R⁹ is hydrogen, or C1-C10 alkylcarbony,

R¹⁰ is hydrogen, and

R¹¹ is hydrogen or acetyl.

3. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is methyl, R¹ is H and R² is OH.

4. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is amino alkyl carbonyi, R¹ is H and R² is OH.

5. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is cyano, R¹ is an amino group, and R² is H.

AMENDED CLAIMS

[received by the Internationa l Bureau on 12 August 1997 ( 12.08.97) ; original claims - 1 -5 replaced by amended claims 1 -5 ( 3 pages ) ]

1. A pharmaceutical composition of an erythromycin derivative combined with acetylsulfisoxazole according to the structural formulas:

where R is hydrogen;

C₁-C₁₀ alkylcarbonyl, or substituted C₁-C₁₀ alkyl wherein said substituent is amino or cyano;

R¹ and R² are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.

2. A pharmaceutical composition of a erythromycin derivative combined with acetylsulfisoxazole according to the structural formula:

and the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein

R¹ is hydrogen,

C₁-C₁₀ alkylcarbonyl or unsubstituted or substituted.

C₁-C₁₀ alkyl [where] wherein said substituent is amino or cyano;

R² and R³ are hydrogen;

R² and R³ together are oxo; R⁴ is hydrogen or C₁-C₁₀ alkylcarbonyl;

R⁵ and R⁶ are independently hydrogen, hydroxy or amino;

R⁵ and R⁶ together are oxo or oximino:

R⁷ and R⁸ are independently hydrogen. C₁-C₁₀ alkyl or phenylsulfonyl;

R⁹ is hydrogen, or C₁-C₁₀alkylcarbonyl,

R¹⁰ is hydrogen, and

R¹¹ is hydrogen or acetyl.

3. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is methyl, R¹ is H and R² is OH.

4. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is amino alkyl carbonyi, R¹ is H and R² is OH

5. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:

wherein R is cyano, R¹ is an amino group, and R² is H.